美国Trovagene   www.trovagene.com  
是一家致力于运用Transrenal DNA (Tr-DNA)技术开发DNA检测的分子诊断公司，它所开发的这种分子检测能够在一次反应中检测出NPM1的所有45种已知变异。这一结果将帮助医师对这种疾病的预后、治疗和监控。该检测也可以在抗AML药物临床试验中对AML患者进行层。
  Xenomics的技术采用的是安全、简易的尿液收集方法并且应用广泛，其应用包括产前检查、肿瘤检测和监控、组织移植、传染病监测、法庭身份确认所需的遗传检测、药物开发和反生物恐怖主义研究。

 Trovagene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company’s founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney (“transrenal” or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.
VALUE PROPOSITION
Targeting transrenal markers will allow us and our partners to develop genetic testing using non-invasive and easy-to-obtain urine samples rather than other more invasive methods, such as traditional blood testing. We are exploring a broad range of clinical utilities where transrenal DNA technology holds the potential to replace complex and less robust earlier technologies based on circulating cells and nucleic acids in blood

Trovagene is leveraging its platform to develop faster, cheaper, less invasive diagnostics, aligned with the current industry shift into personalized medicine. Our diagnostics will enhance the likelihood that the right patient gets the right treatment at the right time.

Transrenal molecular tests will make it easier to address important health problems worldwide and will lead to significant advancements in personalized medicine for improved patient care.
BUSINESS GOALS
Trovagene (from the Italian root word meaning “to find”) is initially targeting medical conditions in which the standard of care requires samples that are difficult, painful, invasive or dangerous to obtain and analyze as well as conditions for which no diagnostic tests currently exist. These targets include tests for the rapid and convenient screening for, detection and monitoring of infectious diseases, cancer, prenatal genetic testing, and the monitoring of organ/cell transplants. 
INTELLECTUAL PROPERTY
Trovagene has a dominant patent position as it relates to transrenal molecular testing. We have issued U.S. and European patents that cover any and all testing for nucleic acid targets that pass through the kidney. In addition to these core patents we have numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing. This patent position rivals the importance of the Roche PCR and Gen-Probe ribosomal RNA patents in the molecular diagnostic field.